Bone turnover markers and bone mineral density response with risedronate therapy: Relationship with fracture risk and patient adherence

Journal of Bone and Mineral Research

Volumn 26, Issue 7, 2011, Pages 1662-1669

  Eastell, Richard ^a   Vrijens, Bernard ^b   Cahall, David L ^c   Ringe, Johann D ^d   Garnero, Patrick ^e   Watts, Nelson B ^f  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b AARDEX Group Ltd   (Belgium)

^c SANOFI   (France)

^d UNIVERSITY OF COLOGNE   (Germany)

^e INSERM   (France)

^f UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Adherence; Bone mineral density; Bone turnover markers; Osteoporosis; Risedronate

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; RISEDRONIC ACID; VITAMIN D;

AGED; ARTICLE; BLOOD LEVEL; BONE DENSITY; BONE TURNOVER; CLUSTER ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FRACTURE; FRAGILITY FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POSTMENOPAUSE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SPINE FRACTURE; TREATMENT RESPONSE; URINALYSIS; VERTEBRA FRACTURE;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; ETIDRONIC ACID; FEMALE; FRACTURES, BONE; HUMANS; INCIDENCE; PATIENT COMPLIANCE; RISK FACTORS;

EID: 79959495797     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.342     Document Type: Article

References (49)

1. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843: 1-129.
2. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res. 1996; 11: 1531-1538. (Pubitemid 26331009)
3. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD,. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res. 2000; 15: 1526-1536. (Pubitemid 30484522)
4. Szulc P, Delmas PD,. Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int. 2008; 19: 1683-1704.
5. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J,. Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int. 2000; 11: S2-17.
6. Delmas PD, Hardy P, Garnero P, Dain M,. Monitoring individual response to hormone replacement therapy with bone markers. Bone. 2000; 26: 553-560. (Pubitemid 30301646)
7. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD,. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003; 18: 1051-1056. (Pubitemid 37294942)
8. Chesnut CH 3rd, Bell NH, Clark GS, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med. 1997; 102: 29-37. (Pubitemid 27089984)
9. Fink E, Cormier C, Steinmetz P, Kindermans C, Le Bouc Y, Souberbielle JC,. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int. 2000; 11: 295-303. (Pubitemid 30417181)
10. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD,. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994; 79: 1693-1700.
11. Eastell R, Hannon RA, Garnero P, Campbell MJ, Delmas PD,. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res. 2007; 22: 1656-1660. (Pubitemid 351235131)
12. Bonnick SL, Shulman L,. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med. 2006; 119 (4 Suppl 1): S25-S31.
13. Watts NB, Cooper C, Lindsay R, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom. 2004; 7: 255-261. (Pubitemid 39178892)
14. Deal CL,. Using bone densitometry to monitor therapy in treating osteoporosis: pros and cons. Curr Rheumatol Rep. 2001; 3: 233-239.
15. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282: 1344-1352. (Pubitemid 29483192)
16. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000; 11: 83-91. (Pubitemid 30099515)
17. Looker AC, Bauer DC, Chesnut CH 3rd, et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporosis Int. 2000; 11: 467-480.
18. Bjarnason NH, Christiansen C,. Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone. 2000; 26: 561-569. (Pubitemid 30301647)
19. Delmas PD, Vrijens B, Eastell R, et al. Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2007; 92: 1296-1304. (Pubitemid 46556401)
20. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M,. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008; 17: 1114-1117. (Pubitemid 351731741)
21. Clowes JA, Peel NF, Eastell R,. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004; 89: 1117-1123. (Pubitemid 38368399)
22. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C,. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004; 15: 1003-1008. (Pubitemid 40064656)
23. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J,. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004; 48: 271-287. (Pubitemid 38781153)
24. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006; 81: 1013-1022. (Pubitemid 44175011)
25. Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM,. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2010; 21: 1943-1945.
26. Lombas C, Hakim C, Zanchetta JR,. Compliance with alendronate treatment in an osteoporosis clinic [abstract]. J Bone Miner Res. 2001; 16 (Suppl 1): S529.
27. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005; 165: 2414-2419. (Pubitemid 41640855)
28. Downey TW, Foltz SH, Boccuzzi SJ, Omar MA, Kahler KH,. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J. 2006; 99: 570-575. (Pubitemid 43999919)
29. Van Staa TP, Leufkens HGM, Cooper C,. Is persistence to bisphosphonate therapy related only to dosing regimen? [abstract]. Osteoporos Int. 2006; 17 (Suppl 1): P282.
30. Cramer JA, Gold DT, Silverman SL, Lewiecki EM,. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007; 18: 1023-1031. (Pubitemid 47019996)
31. Weycker D, Macarios D, Edelsberg J, Oster G,. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int. 2007; 18: 271-277. (Pubitemid 46233172)
32. Miller NH,. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med. 1997; 102: 43-49. (Pubitemid 27147947)
33. Zyczynski TM, Coyne KS,. Hypertension and current issues in compliance and patient outcomes. Curr Hypertens Rep. 2000; 2: 510-514.
34. Claxton AJ, Cramer J, Pierce C,. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001; 23: 1296-1310. (Pubitemid 32804122)
35. Huybrechts KF, Ishak KJ, Caro JJ,. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006; 38: 922-928. (Pubitemid 44498580)
36. Sunyecz JA, Mucha L, Baser O, Barr CE, Amonkar MM,. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int. 2008; 19: 1421-1429.
37. Genant HK, Wu CY, van Kuijk C, Nevitt MC,. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993; 8: 1137-1148. (Pubitemid 23261108)
38. Delmas PD, van de Langerijt L, Watts NB, et al. IMPACT Study Group. Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res. 2005; 20: 557-563. (Pubitemid 40393062)
39. Vrijens B, Ringe JD, Watts NB,. Electronic monitoring of adherence to therapy in postmenopausal osteoporosis: the IMPACT study. Proceedings of the 30th European Symposium on Calcified Tissues 2003, May 8-12, Rome, Italy.
40. Centers for Disease Control and Prevention (CDC). Osteoporosis among estrogen-deficient women-United States, 1988-1994. MMWR Morb Mortal Wkly Rep. 1998; 47: 969-973.
41. Bauer DC, Black DM, Garnero P, et al. Fracture Intervention Trial Study Group. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004; 19: 1250-1258. (Pubitemid 41094365)
42. Delmas PD, Munoz F, Black DM, et al. HORIZON-PFT Research Group. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res. 2009; 24: 1544-1551.
43. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD,. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res. 2004; 19: 394-401. (Pubitemid 38787394)
44. Reginster JY, Sarkar S, Zegels B, et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone. 2004; 34: 344-351. (Pubitemid 38177616)
45. Rabenda V, Reginster JY,. Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures. Osteoporos Int. Published online January 16, 2010; DOI: 10.1007/s00198-009-1155-z.
46. Blouin J, Dragomir A, Moride Y, Ste-Marie LG, Fernandes JC, Perreault S,. Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. Br J Clin Pharmacol. 2008; 66: 117-127. (Pubitemid 351822168)
47. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008; 19: 811-818.
48. Cotté FE, Mercier F, De Pouvourville G,. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis. Clin Ther. 2008; 30: 2410-2422.
49. McClung MR, Geusens P, Miller PD, et al. Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001; 344: 333-340. (Pubitemid 32107641)